Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

about

Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer

P2860

Q48306032-754F092C-BFC6-4B08-A8A9-CF85059EB406 Q57105411-5F4A3CC2-4D31-414D-94A4-813A6FBCED95

P2860

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q40126367

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Polymorphisms associated with ...... l in metastatic breast cancer.

@en

type

Item

label

Polymorphisms associated with ...... l in metastatic breast cancer.

@en

prefLabel

Polymorphisms associated with ...... l in metastatic breast cancer.

@en

P1476

Polymorphisms associated with ...... l in metastatic breast cancer.

@en

P2093

Carlos Álvarez

http://www.w3.org/2001/XMLSchema#string

Cecilia Cueto-Felgueroso

http://www.w3.org/2001/XMLSchema#string

Cristina Pernaut

http://www.w3.org/2001/XMLSchema#string

Eva Ciruelos

http://www.w3.org/2001/XMLSchema#string

Lucia Inglada-Pérez

http://www.w3.org/2001/XMLSchema#string

Luis Manso

http://www.w3.org/2001/XMLSchema#string

Pablo Villalba

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR signaling in growth control and disease

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

Defining the role of mTOR in cancer

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Clinical pharmacokinetics of everolimus.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.

P304

e0180192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0180192

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mercedes Robledo

Cristina Rodríguez-Antona

Tomás Pascual

Maria Apellaniz-Ruiz

P577

2017-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28727815

http://www.w3.org/2001/XMLSchema#string

P932

5519037

http://www.w3.org/2001/XMLSchema#string

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

about

P2860

P2860

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932